Lupin Receives US FDA Tentative Nod For Pitolisant; Shares Up 0.41%

Mumbai, March 25: Lupin Limited has received tentative approval from the United States Food and Drug Administration for its Pitolisant Tablets in strengths of 4.45 mg and 17.8 mg.

The approval relates to Lupin’s Abbreviated New Drug Application for the product, which is indicated for conditions aligned with the reference listed drug Wakix. The exchange filing on Wednesday confirms that the product has been deemed bioequivalent to the reference drug as per regulatory standards.

Manufacturing is slated to be undertaken at Lupin’s Nagpur facility in India, reinforcing the company’s domestic production capabilities for regulated markets. Tentative approvals typically indicate that the product meets all scientific and regulatory requirements but may await patent or exclusivity clearance before commercial launch.

Stock Market Snapshot

Lupin share price moved modestly higher following the disclosure. As of 9:42 IST on March 25, 2026, the stock was trading at ₹2,341.40, up ₹9.60 or 0.41%, according to exchange data.

The stock opened at ₹2,338.70 and touched a high of ₹2,355.00 during the session so far, indicating a limited but positive market reaction to the regulatory update.

The price movement suggests incremental investor confidence tied to pipeline visibility and progress in the US generics segment, though gains remained contained in early trade.

Company Maintains Strong Global Pharma Footprint

Lupin operates as a global pharmaceutical company with a presence across more than 100 markets. Its portfolio spans branded and generic formulations, biotechnology products and active pharmaceutical ingredients.

The company maintains multiple manufacturing sites and research centres globally, supporting both regulated and emerging market operations. Its therapeutic focus includes respiratory, cardiovascular, anti-diabetic and central nervous system segments.

The Nagpur facility, referenced in the filing, forms part of Lupin’s broader manufacturing network catering to export markets including the United States.

Regulatory Progress Supports Pipeline Visibility

The tentative approval adds to Lupin’s pipeline of filings in the US market, a key revenue geography for Indian pharmaceutical exporters.

While commercialisation timelines remain subject to regulatory exclusivity conditions, such approvals are typically viewed as milestones that enhance medium-term product visibility.

Market participants are likely to track further updates on final approval status and launch timelines, particularly in the context of competitive intensity in the US generics space.

Source;

• https://www.nseindia.com/get-quote/equity/LUPIN/Lupin-Limited
• https://nsearchives.nseindia.com/corporate/Lupin2_25032026091554_SE_Letter_25032026.pdf